-
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
•
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful completion of a Series C financing round, raising hundreds of millions of renminbi. The funding was led by Nanjing Jiangning High Tech Zone Science and Technology Entrepreneurship Investment Management Co., Ltd and Huaxing Kangping Pharmaceutical…
-
Neurodawn Pharmaceutical and China Medical System Holdings Ink Licensing Deal for Y-3
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has entered into a significant licensing deal with China Medical System Holdings (CMS; HKG: 0867), a fellow Chinese firm. The agreement grants CMS exclusive promotion rights for Neurodawn’s anti-ischemic stroke brain cell protective agent, Y-3, across mainland China, Hong Kong, and Macau. Y-3: A Promising…
